The Osteoporosis W orking Group, K in g F aisal S pecialist H o sp ita l a n d Research Center
he subject of postmenopausal osteoporosis con tinues to be an important one for clinicians and epidemiologists, as the incidence of osteoporotic fracture continues to increase and the burden of such fractures on the health economy is expected to rise to astonishing figures. In the United States alone, 1.5 million osteoporotic fractures occur annually, with estimated direct expenditures of over $14 billion (American Association O f Clinical Endocrinologists guidelines). In the United Kingdom, 200 000 fractures per year are attributed to osteoporosis at an annual cost of over £940 million (Royal College O f Physicians guidelines). In Asia, the projected number of hip fractures is 3 million in the year 2050.1 Although these costs are considerable, the price of pre vention and treatment for osteoporosis could be as high. Therefore, recommendations and guidelines for detection, screening, prevention and management of osteoporosis are obviously needed.
A recent report by The US Preventive Services Task Force based on a review of evidence found that there is good reason for screening women for osteoporosis at age 65 and above, or between age 60 to 64 in the presence of significant fracture risk factors. This recommendation is in contrast to a previous recommendation made by the same task force against routine screening in 1997. Still there are no recom mendations by the task force on screening younger post menopausal women.2 A year 2000 consensus conference by N IH noted that the value of universal screening was not yet established. The National Osteoporosis Foundation and the American Association of Clinical Endocrinologists have made more liberal recommendations.
Guidelines for prevention and treatment can also be controversial, especially when it comes to the level of bone mineral density (BMD) at which one would initiate preven tion or treatment measures with pharmacological agents. Recent studies3,4 have shown an unexpected increased risk of cardiovascular events in postmenopausal women with the use of hormone replacement therapy (HRT). In addi tion, there was an increase in the risk of breast cancer and venous thrombosis. HRT has been regarded as a corner stone, and often a first-line therapy, together with calcium, in the prevention and treatment of postmenopausal osteo porosis. Many women used this agent with the idea that it would also decrease cardiovascular risks. But the above findings have made it difficult to use HRT without accept ing the risks involved. The value of newer pharmacological agents like bisphosphonates and selective estrogen receptor modulators (SERMs) have been established in treating postmenopausal osteoporosis, but their role in fracture prevention for subjects who are not osteoporotic has not been proven, although such therapy may prevent bone loss and improve BM D. 5 It is clear therefore that practitioners need guidelines and recommendations for a rational and evidence-based approach to this problem. Such guidelines or recommen dations should ideally be based on studies and projections made in the same population where these recommendation would be applied. Some of the factors that would influence these guidelines in a certain population are: 1) the inci dence and the medical and financial impact of osteoporotic fractures in this population, 2) the prevalence of osteopo rosis, especially among postmenopausal women, 3) the priority of osteoporosis compared to other public health issues in that society, 4) the cost-effectiveness of diagnostic, preventive and treatment measures, and 5) lifestyle factors and conditions that might impact the quality of bone or the risk of fracture in the young, postmenopausal women, and in the elderly (e.g., sun exposure, exercise, level of physical activity, chance of falling).
Data on the prevalence of osteoporosis, rates of verte bral and hip fractures, and the correlation of BMD and other fracture risk factors with fracture rates is generally sparse or lacking for Saudi Arabia, Gulf countries, and other Middle Eastern Arab countries. Nevertheless, certain deductions can be made from the available studies and personal observa tions: 1) BMDs are generally lower in the population of this region compared with the western population, with a higher percentage of young subjects and premenopausal women with osteopenia.6 However, a correlation between BMD and fracture rates has not been established in this region.
2) Fracture rates are lower than those reported in the west, but more than those reported in the Far East.7 8 Thus, us ing BMD parameters alone will likely result in unnecessary treatment and might not be cost effective. 3) Vitamin D deficiency is still a common problem in this region.
There is an obvious need for local guidelines based on local data and experience. Local guidelines are not intended to replace the individual judgment needed for best use of the evidence while taking in account local and cultural factors. The recommendations in this document are based on a vast amount of published literature and consensus guidelines on the diagnosis, prevention, and management of osteoporosis. Also, it took into account local considerations. These recom mendations are subject to change pursuant to the following: 1) medical judgment relative to individual patient needs, 2) availability of data on the epidemiology of osteoporosis and osteoporosis-related fractures, and appropriate reference ranges of bone mineral density in Saudi Arabia; 3) availability of new diagnostic strategies and therapies for prevention and treatment of osteoporosis, as well as cost-effectiveness studies, and 4) a definition of the priority of osteoporosis compared to other public health conditions in this country.
D e fin itio n o f osteoporosis
Osteoporosis is a progressive systemic skeletal disorder characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture (NIH Consensus Statement). A fragility fracture is one that occurs as a result of either an injury that is insufficient to fracture normal bone, or as a result of no identifiable trauma (Canadian guidelines). Osteoporosis is a function of bone mass achieved at maturity and subsequent bone loss that is accentuated in the early postmenopausal period, and is influenced by certain risk factors.
O steopenia/osteoporosis and fractures in th e region
Local and regional information about osteoporosis and fracture rates is sparse. In a study of 483 postmenopausal Saudi women 52 to 62 years of age, A1 Desouki found the rate of osteopenia and osteoporosis to be 34% and 24%, respectively.10 In another study by A1 Ghannam et al of 321 healthy Saudi women, the prevalence of osteoporosis was 3.2% for the 31-to 40-year age group, 5.9% for the 41-to 50-year age group, and 28% for the >50-year age group. The prevalence of osteopenia in the respective age groups was 38%, 38%, and 66%. Severe vitamin D deficiency was pres ent in 52% of the subjects.11 BMD in healthy Saudi females is significantly lower than in their western counterparts. This may be due in part to the prevalent vitamin D deficiency. Vitamin D deficiency may cause osteomalacia and affect the BMD measurement. Correction of the deficiency can result in improvement of BMD.
There are also limited data on fracture rates in the re gion. In a study from Lebanon, Baddourah et al found the lifetime risk for all fractures to be 9.3% in males, and 16.7% in females.7 This rate is higher than other Asian countries, but less than Europe. In Kuwait, Memon et al found hip fracture age-standardized annual rates of 29.5/100 000 in fe males, and 20/100 000 in males.12 These rates are also higher than what has been reported form other Asian countries. Al-Nuaim et al estimated the incidence of proximal femur fractures for women per 100,000 population to be 4.5 in the 40-to 49-year age group, 14.6 for the 50-to 59-year age group, 79 for the 60-to 69-year age group, and 394 for the >70-year age group. The respective rates for men were 7, 22, 36 and 251 -8 The higher incidence of fractures in males com pared to females in the age group 40-to 59-year age group is believed to be due to lifestyle factors and involvement in activities that may lead to fractures. It is generally believed that fracture rates in the Saudi population are less than what has been reported from the West. This might be related to genetic factors that may influence bone quality, or cultural and lifestyle differences.
Clinical m anifestations and complications
Osteoporosis is a silent disease, as bone loss occurs without symptoms. Most of the time there are no warning signs until a fragility fracture occurs. Osteoporosis-related fractures may occur in any bone but are most likely to occur at sites of low bone mass. The most typical sites of osteoporosis related fractures are the vertebrae, distal radius, proximal femur, and ribs.
The morbidity of osteoporosis comes mainly from frac tures and their potential complications. Vertebral compres sion fractures are associated with pain, deformity, disability, and increased mortality. 13 The most serious consequences, however, are those associated with hip fractures. In one study on elderly subjects who sustained hip fractures, the life expectancy was reduced by 1.8 years or 25% compared to a matched population. There was also a significant increase in morbidity and health costs in those who had hip fracture.14
Evaluation/diagnosis
Optimal evaluation consists of establishing the diagnosis of osteoporosis on the basis of bone mass assessment, es- tablishing the fracture risk, and determining the need for instituting therapy. Bone strength is related to the density and quality of bone. There is at present no accurate measure for bone quality. BMD is considered a surrogate measure of bone strength. Dual-energy x-ray absorptiometry (DXA) is the preferred technique to measure BMD, and is the tech nique used at most centers. Quantitative ultrasound is useful for screening for osteoporosis. The hip is the preferred site for BMD measurement due to the high predictive value of hip BMD for fracture risk, particularly in the elderly.15 BMD measurement at the spine predicts spine fracture better than measurements at other sites. However, spine changes may affect BMD measurement. The World Health Organization (WHO) has established an opera tional definition for osteoporosis based on BMD as measured by DXA, commonly expressed as aT-score (Table 1) .
A history and a physical examination to evaluate fracture risks should include assessment for loss of height and change in posture. Laboratory evaluation for secondary causes of osteo porosis should be considered when osteoporosis is diagnosed. Serum calcium, phosphorus, creatinine, vitamin D, a complete blood count and thyroid stimulating hormone (TSH) levels are usually sufficient baseline tests. Further laboratory tests can be done as clinically appropriate, such as parathyroid hormone level, urine free cortisol, liver function tests, or serum immune electrophoresis. Biochemical indices of skeletal turnover could potentially be helpful in the diagnosis and monitoring of therapy. However, as their role has not been frilly elucidated, they are not yet recom mended in routine clinical management. The decline in bone resorption markers in response to antiresorptive therapy occurs before a significant change in BMD, which may explain the decrease in fracture rates seen early with such therapy, before changes in BM D.16
DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS

Fracture risk factors and fra ctu re index
The FRACTURE Index is a simple clinical tool that was found to be helpful in assessing the risk of hip, vertebral and non-vertebral osteoporotic fractures in elderly post menopausal women with and without BMD T-scores. 9 The FRACTURE Index comprises several variables/risk factors. These variables and the score associated with each variable are summarized in Table 2 . Subjects with a score of 4 without BMD, or 6 with BMD are candidates for screen ing, prevention or treatment as appropriate. These risk fac tors could also be useful in assessing the risk of osteoporotic fractures in elderly m en.17 This scoring system has however not been evaluated in secondary osteoporosis or steroid-in duced osteoporosis.
Indications fo r BM D m easurem ent
Some international guidelines for osteoporosis screening rec ommend BMD testing for all women age 65 years or older, and for postmenopausal women under the age of 65 years (especially, 60-64 years) who have one or more additional high risk factors for osteoporosis.2 However, as the BMD is generally lower in Saudi women compared to their western counterparts, they may develop osteoporosis and fractures at an earlier age. It is also relevant that physical activity, and therefore the risk of falling, may be less in elderly females older than 65 years, according to local cultural habits. Thus, it is reasonable to start screening postmenopausal Saudi women at an earlier age than that recommended for western women. We stress that BMD measurement should only be done if it will influence manage ment decisions. We recommend BMD measurement in the situations described in Table 3 .
Prevention
Prevention is the most important measure in addressing low BMDs in the youth and in women during reproductive age. Frequent pregnancies and lactation may predispose women in our society to lower BMDs. Thus, proper nutritional and fam ily planning advices are warranted for this group of women. Another important target for prevention is postmenopausal women and those with conditions predisposing to osteopo rosis.
Initiatives to prevent osteoporosis should include the fol lowing measures:
• Optimal nutrition in youth to achieve high peak bone mass, including adequate intake of calcium and Vitamin D • Regular weight bearing exercise • Identification and treatment of subjects with Vitamin D deficiency, especially in children, females in the reproduc tive age group, and the elderly • Avoidance of tobacco smoking and excessive alcohol intake • Assessment of every postmenopausal woman for risk of osteoporosis to determine the need for diagnostic tests and prevention /treatment • Early treatment of secondary causes of osteoporosis (e.g., thyrotoxicosis, smoking, primary hyperparathyroidism, other secondary causes) • Prevention and early treatment of osteoporosis in pa tients who are receiving high-dose steroid therapy, or other drugs that may contribute to osteoporosis
The value of antiresorptive agents for fracture prevention has not been proven for those with no prior fractures, or with BMD greater than -2.5 standard deviations from the reference mean, although such agents might improve or stabilize BMD.5 Therefore, their use should be limited to those with history of fractures or with multiple risk factors for fractures.
M an ag em en t
Important goals in the management of osteoporosis are to pre vent fractures, treat pain and discomfort caused by osteoporosis complications, and improve bone density/quality, if possible. Non-pharmacological measures to manage osteoporosis in clude changing adjustable lifestyle risk factors, preventing falls, maintaining or improving mobility, and increasing weight bearing exercises. Pharmacological measures include treating secondary causes of osteoporosis, and associated disorders, treating pain, discomfort and other associated morbidity, and increasing bone mass. Drugs for osteoporosis primarily reduce bone turnover by inhibiting osteoclast activity. Although they may lead to an early increase in bone mass, the drugs mainly prevent further loss of bone. Agents that primarily increase bone formation (e.g. parathyroid hormone) have only recendy become available.
Classes o f drugs available fo r prevention and treatm en t o f osteoporosis (See APPENDIX I and II)
C a lc iu m a n d V ita m in D s u p p le m e n ta tio n
These agents are not sufficient as a sole treatment of osteoporo sis, but rather as adjuncts to therapy. They are however essential in any prevention or treatment plans. Calcium and vitamin D decrease bone loss in postmenopausal women, and may reduce the risk of vertebral fractures and possibly non-vertebral frac tures, especially in the elderly and in subjects with low calcium and vitamin D. A recent meta-analysis of the effect of calcium and vitamin D showed only an effect of vitamin D in decreas ing vertebral fractures.18 '20 The recommendation for adequate daily calcium intake, and available products are summarized in Appendix I. For most patients with osteoporosis, diet alone does not provide adequate calcium intake and, therefore, calcium supplementation is nec essary. Calcium supplements are better taken with meals. No more than 500 mg of elemental calcium should be taken at a time since excess calcium may not be absorbed as effi- BMD can be measured in m onitoring tre a tm e n t ciently. Calcium should not be taken at the same time as iron supplements as the absorption of both products may be ad versely affected when given concurrently. The recommended total daily intake of vitamin D is 400 IU for men and women under 50 years, and 800 IU for men and women 50 years. An alternative to supplementation is exposure to the sun for 10 to 15 minutes every day, 2 to 3 times/week.
H orm on e rep la cem en t th e ra p y (H R T )
HRT improves BMD in postmenopausal women.21 Most of the studies however on the effect of HRT in fracture preven tion were retrospective and not well designed. The recent Womens Health Initiative (WHI) prospective study did however indicate an effect in decreasing the risk of vertebral and non-vertebral fractures, including hip fractures.3,22 HRT has been used widely for prevention and treatment of osteoporosis in postmenopausal women. The W HI study3
showed an increased risk of invasive breast cancer, coronary artery disease, venous thromboembolism (pulmonary, deep vein), and stroke in healthy postmenopausal women who received a daily dosing regimen of 0.625 mg of conjugated equine estrogen (Premarin) plus 2.5 mg of medroxyproges terone acetate (Provera) compared to women who received placebo. These results call for caution. When HRT is used for osteoporosis prevention and treatment, women and their physicians should weigh the benefits of long-term HRT against the subjects personal risks for coronary artery disease, stroke, venous thromboembolic disease, and breast cancer. These results may not apply to other forms of estro gen replacement, but caution is warranted. Additionally, the W HI group states the following in relation to estrogen plus progestin use: "while short term use was not studied, women taking the therapy for relief of postmenopausal symptoms may reap more benefits than risks." At this point however, Calcitonin has analgesic properties and can decrease the pain associated with acute vertebral fractures. As calcitonin causes only modest improvement in BMD and is expensive, its use must be limited to those who are unable to tolerate other agents, or those in whom other agents are contraindicated, or when pain control is an additional desired goal. Table 4 is a summary of the effects on BMD and fracture risk of various pharmacological agents that are generally used for the prevention and treatment of osteoporosis in postmenopausal women, according to randomized con trolled trials.
T rea tm e n t reco m m en datio n s
In view of the lower fracture rates in our population, we might have to be more conservative in defining those who need potentially expensive pharmacological treatment. In addition to the level of BMD, fracture risk factors might help in defining a higher risk group that would be targeted for therapy.9 Based on BMD findings and fracture risk fac tors, the task force makes the recommendations shown in Table 5 .
Prem enopausal osteoporosis
W hen osteoporosis is suspected in a premenopausal woman, based on a fragility fracture, clinical or radiologic findings, or multiple high-risk factors, a BMD measure ment is indicated. If osteoporosis is present, every effort should be made to look for and correct secondary causes. Important secondary causes of low BMD in this age group include vitamin D deficiency, osteomalacia, primary and secondary hypogonadism (hyperprolactinemia, anorexia nervosa, premature ovarian failure), use of steroids, che motherapy, and radiation. Management of these subjects includes an adequate intake of calcium and vitamin D, and pharmacological therapy. Hypoestrogenic subjects could be treated with HRT. If not hypoestrogenic, or if there is fur ther significant loss of bone mass while an HRT, consider therapy with bisphosphonates. Calcitonin may be used in case of intolerance to, or presence of a contraindication to bisphosphonates.
O steoporosis in men
Osteoporosis in men is not uncommon. Risk factors for osteoporosis in men are similar to those in women. W hen osteoporosis is suspected in men, a BMD measurement is indicated. The BMD T score seems to be a reliable indica tor for predicting fractures in men as well. When osteo porosis is established, secondary causes should always be looked for. An adequate medical history, physical examina tion and appropriate investigations are warranted. Some of the important secondary causes for osteoporosis in men are alcoholism, tobacco smoking, hyperthyroidism, Cushings disease, steroid use, multiple myeloma, hyperparathyroid ism, use of heparin, and primary or secondary hypogonad ism. Vitamin D deficiency should also be ruled out. The management of osteoporosis in men includes identifying and correcting underlying, secondary causes, ensuring an adequate calcium and vitamin D intake, if deficient, en couraging weight-bearing exercise, reducing or stopping tobacco smoking and alcohol intake, and pharmacologic therapy. If hypogonadism is present, treatment should con sist of testosterone. If hypogonadism is not present, treat ment should consist of a bisphosphonate, or calcitonin in the case of intolerance to, or in the presence of contraindi cations to bisphosphonates.
G lucocorticoid-induced osteoporosis
Our recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis (Figure 1 
